Latest News

Category: News

See all

Telix to Showcase Innovation in Urology at AUA Annual Meeting, including New ZIRCON Phase III Data in Very Small Renal Masses

Events, News,

Telix will showcase further detailed analyses from the Company’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be presented in a late-breaking oral presentation at the American Urological Association (AUA) Annual Meeting being held in Chicago from 28 April to 1 May...

Read more

Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

ASX, News,

Telix today announces the expansion of its artificial intelligence (AI) capability with the signing of an agreement to acquire Vienna-based Dedicaid GmbH (Dedicaid), a spin-off of the Medical University...

Read more

Notice of Annual General Meeting 2023

ASX, News,

Telix is pleased to provide notice that the Annual General Meeting of the Shareholders of Telix Pharmaceuticals Limited (ACN 616 620 369) will be convened on Wednesday 24 May...

Read more

Telix-Grand Pharma Investor Webcast

Events, News,

Telix is pleased to provide a video recording of the joint webcast with Telix’s exclusive partner for the Greater China market, Grand Pharma held on 20 April 2023. ...

Read more

Activities Report and Appendix 4C for March quarter: Telix delivers its first $100M revenue quarter

ASX, News,

Telix today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2023 (Q1 2023). All figures are in AUD$ unless otherwise...

Read more

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

ASX, Clinical, News,

Telix today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) of using olaratumab to selectively deliver both...

Read more

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

ASX, Clinical, News,

Telix today announces the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a Phase I study of TLX101 investigational therapy (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in...

Read more

Telix Quarterly Results and Investor Call / Webcast Notification

ASX, News,

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 31 March 2023 on Monday 17 April 2023 at market...

Read more

FDA Approves Expanded Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Events, News,

Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga...

Read more

Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented in “Game Changing” Session at EAU

Events, News,

Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:...

Read more